NICE is set to evaluate numerous potential treatments for Alzheimer’s disease in the coming years. This year, they rejected two new drugs, lecanemab and donanemab, due to the high cost and required intensive monitoring for side effects. Despite not being available through NHS, these drugs have been approved by the MHRA and offer hope for future treatments. Alzheimer’s Research UK sees this as a stepping stone for the development of safer and more effective therapies that could slow, stop, or reverse dementia. The focus of future treatments will be on removing harmful proteins, protecting brain cells, and restoring damage caused by the disease.
Source link
Alzheimer’s disease: What treatments could be rolled out in the next few years?
